January 26, 2026 a 03:43 pm
VRTX: Fundamental Ratio Analysis - Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals, a leader in biotechnology, continues to showcase strong performance through its innovative treatments for cystic fibrosis and promising pipeline for other serious diseases. The stock is currently rated highly for its financial health, with a robust innovation track driving its future prospects. Analysts maintain a favorable outlook, supporting a 'Buy' consensus for VRTX.
Fundamental Rating
Vertex Pharmaceuticals shows a strong fundamental position with high scores in key areas.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 3 | |
| Price to Earnings | 2 | |
| Price to Book | 2 |
Historical Rating
Comparing past and current performance data shows consistency in Vertex Pharmaceuticals' financial health.
| Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-01-23 | 4 | 5 | 5 | 5 | 3 | 2 | 2 |
| -- | 0 | 5 | 5 | 5 | 3 | 2 | 2 |
Analyst Price Targets
Analysts estimate a strong price range for VRTX with a healthy upside potential.
| High | Low | Median | Consensus |
|---|---|---|---|
| 564 | 414 | 525 | 504.73 |
Analyst Sentiment
The overall analyst sentiment remains positive, supporting further growth prospects for VRTX.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 43 | |
| Hold | 12 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Vertex Pharmaceuticals Incorporated is well-positioned in the biotechnology sector, driven by a strong portfolio of cystic fibrosis treatments and a promising development pipeline. The company's financial fundamentals are solid, as reflected in the high scores in key financial metrics. While the stock offers strong potential for growth, as supported by analyst price targets and sentiment, investors should remain cautious of market volatility and regulatory challenges inherent in the biotech industry.